Six years ago, ADMA Biologics was losing nearly two dollars for every dollar it brought in. The company made a single class of medicine, plasma-derived immunoglobulins (proteins collected from donated blood and given to patients whose immune systems cannot make enough of their own), and it was burning cash at a rate that made survival the main question. Then something changed. Revenue doubled, then doubled again, then crossed half a billion dollars. The losses turned into profits. And yet, as of October 13, 2026, the stock sits exactly half its 52-week high. That gap between what the filings show and what the market is paying is the story.
In one breath
ADMA’s filed numbers show a company that went from deep losses to a 46% net margin in 2024, then held profitability through the first half of 2026 at a 69% gross margin. The stock is priced, per BullScope’s valuation dataset (methodology available at bullscope.ai/methodology), at a price-to-sales ratio in the bottom 10% of its own decade (BullScope valuation dataset; methodology at bullscope.ai/methodology), as if the growth that produced those margins is already over. Whether the growth is slowing or merely digesting is the open question the market has not yet answered.
From the brink to the black
The turning point was not a single event but a sequence. ADMA’s flagship product, ASCENIV, is a high-concentration immunoglobulin therapy approved for adults with weakened immune systems. For years it existed mostly as a promise: approved by the FDA, manufactured at ADMA’s Boca Raton facility, but not yet generating the volumes that would cover the fixed costs of running a plasma-processing plant. Those plants are expensive to operate whether or not the vials are full.
The math started working when the vials got full. The 10-K for fiscal year 2025 shows ASCENIV sales up more than half from the year before, carrying nearly the entire revenue line. That one product went from a clinical-stage hope to the engine of a business generating over half a billion dollars in annual revenue. Then, in April 2025, the FDA approved a new production process that ADMA said would lift yields meaningfully from the same plasma volume, meaning more medicine from each donation without buying more raw material. In May 2026, the FDA expanded ASCENIV’s label to cover pediatric patients as young as two, opening a patient population that did not exist for the drug before.
For a reader trying to understand why any of this matters: a drug with a broader approved use can be prescribed to more patients, which is the most direct path to higher revenue a pharmaceutical company has. The pediatric label is not a guarantee of more sales, but it removes a ceiling.
What the filed numbers actually say
The profit story is real and it is recent. Through fiscal years 2020 to 2023, ADMA lost money every single year. The 2024 annual filing was the first to show a positive net margin, and it was not a thin one: 46%, meaning that for every dollar of revenue, nearly half a dollar reached the bottom line after all costs. That is a margin profile more common among software companies than drug manufacturers who buy plasma, process it, and ship refrigerated vials.
The Q2 2026 filing, covering the quarter ended June 30, shows the business holding much of that ground: a 69% gross margin (gross margin is what remains of each revenue dollar after the direct cost of making the product, before overhead and salaries). Net income for the quarter was strong relative to revenue, and the company held well over a hundred million dollars in cash while generating meaningful cash from operations in the quarter alone, meaning the business is funding itself.
One complication sits inside those numbers. BIVIGAM, ADMA’s second immunoglobulin product, saw revenue fall by roughly half year-over-year in Q2 2026. ASCENIV’s growth more than covered the gap, but a business running on one strong product and one declining one carries more concentration risk than the headline revenue figure suggests. The filed numbers do not explain why BIVIGAM is shrinking; they only show that it is.
The short-seller shadow
In March 2026, a short-seller report alleged that ADMA’s 2025 revenue figures were inflated. ADMA refuted the report, and the SEC filings stand as filed. But the episode left a mark: investor sentiment toward the stock cooled, and the share price has not recovered. This is the “mood” side of our framework, where mood means what the market is currently willing to pay regardless of what the filings show. The math, what filed fundamentals justify, and the mood, what today’s price implies, have diverged sharply.
BullScope’s valuation dataset (methodology available at bullscope.ai/methodology) puts ADMA’s current price-to-sales ratio (the price tag per dollar of annual revenue) at roughly 4.5, sitting in the bottom 10% of its own decade-long range based on monthly closing prices from 2016 through October 2026. Both gauges indicate the stock is priced below where it has historically traded relative to its own results. That is not a prediction of anything. It is a description of where the tension lives.
For context on the peer group: Grifols, a larger plasma-products company, trades at a price-to-sales ratio below 1. CSL, the global leader in plasma medicine, trades at roughly 4 times sales. ADMA at 4.5 times sales is not cheap relative to peers, even if it is cheap relative to its own history. The comparison cuts both ways.
The growth rate question
Here is the shift that probably explains the stock’s decline more than anything else. Then, in 2025, revenue growth slowed sharply to 20% year-over-year. In the first half of 2026, year-over-year growth has been roughly flat to low single digits. Q1 2026 revenue of $114.5 million was essentially unchanged from a year earlier. Q2 2026 revenue of $124.4 million was up just 2% year-over-year.
A business that compounded at high double-digit rates for years and then slowed to near-flat will get repriced. Markets pay high multiples for fast growth and ordinary multiples for ordinary growth. The question the filed numbers cannot answer is whether the slowdown is structural, meaning the market for ASCENIV is approaching saturation, or transitional, meaning the pediatric label expansion and the new production yields have not yet shown up in the revenue line. Q3 2026 results are scheduled for November 4, 2026, and that report will be the first real test of which story is true.
A profitable, cash-generative business sitting at the low end of its own historical valuation range presents a different risk profile than a money-losing startup. The open question is not survival but whether the growth that justified a premium multiple is returning, or whether the business has matured into a steady-profit, slower-growth operation, a fine outcome for the enterprise but a different one than the stock’s prior valuation implied.
Reading the numbers
- FY2024 net margin: 46%. Net margin is what survives of each revenue dollar after every cost, including taxes and interest. A 46% net margin means that for every $100 of medicine ADMA sold, $46 reached the bottom line. For comparison, a typical grocery chain keeps about $2. This figure, from the 2024 10-K, marked the first profitable year in the company’s public history.
- Q2 2026 gross margin: 69%. Gross margin, from the Q2 2026 10-Q, is what remains after the direct cost of making the product. Think of a bakery: if flour, labor, and the oven cost $31 for every $100 of bread sold, the gross margin is 69%. ADMA’s 69% means its manufacturing economics are strong, even as overhead and R&D spending eat into the final profit figure.
- Price-to-sales ratio: 4.5, bottom 10% of decade range. The price-to-sales ratio is the total market value of the company divided by its annual revenue, a way of asking how much investors are paying per dollar of sales. BullScope’s valuation dataset (methodology at bullscope.ai/methodology) shows ADMA’s current ratio sits lower than 90% of the readings over the past decade. A household analogy: if a small business historically sold for four to eight times its annual revenue, and today a buyer could acquire it for 4.5 times revenue, that buyer is getting a below-average price by historical standards, though not the lowest ever.
- ASCENIV revenue, Q2 2026: $102.9 million, up 24% year-over-year. ASCENIV is the product doing the work. This figure, from the Q2 2026 earnings release, means ASCENIV alone accounted for 83 cents of every revenue dollar in the quarter. When one product is that dominant, its trajectory is the company’s trajectory.
- BIVIGAM revenue decline: 49% year-over-year in Q2 2026. This figure is drawn from the Q2 2026 earnings release. If ASCENIV is the engine, BIVIGAM is a drag. A 49% drop means the product brought in roughly half what it did a year ago. Sequential improvement (up 26% from Q1 to Q2) suggests the decline may be stabilizing, but the year-over-year comparison remains steep.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-Q for quarter ended March 31, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
- ADMA Q2 2026 earnings release (IR site)
- ADMA Q1 2026 earnings release (GlobeNewswire)
- ADMA press releases, including pediatric label approval (IR site)
- ADMA overview including short-seller context (StockTitan)
- Sell-side consensus data (MarketBeat), note: third-party ratings and price targets are not endorsed by BullScope and are provided for reference only.
- FDA approval of yield enhancement process (ADMA IR)
Disclosure: BullScope holds no positions in ADMA Biologics or any security mentioned in this article. This article is provided for informational and analytical purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. All analysis reflects publicly available information as of the date of publication. Readers should conduct their own research and consult a qualified financial adviser before making any investment decision. BullScope’s valuation methodology is described at bullscope.ai/methodology.
